NeuroOne Medical Technologies Corp 2026年度季度报告

The number of outstanding shares of the registrant’s common stock as of February 13, 2026 was 50,525,995. PART I – FINANCIAL INFORMATION Condensed Statements of Cash Flows for the three months ended December 31, 2025 and 2024 (unaudited)Notes to Condensed Financial Statements (unaudited) Item 1.Legal Proceedings34Item 1A.Risk Factors34 NeuroOne Medical Technologies CorporationNotes to Condensed Financial Statements NOTE 1 – Description of Business and Basis of Presentation NeuroOne Medical Technologies Corporation (the “Company” or “NeuroOne”), a Delaware corporation, is a medical technologycompany focused on the development and commercialization of thin film electrode for continuous electroencephalogram (“cEEG”)and stereoelectrocencephalography (“sEEG”) recording, monitoring, ablation and stimulation solutions to diagnose and treat patientswith epilepsy, trigeminal neuralgia, Parkinson’s disease, dystonia, essential tremors, chronic pain due to failed back surgeries and other The Company has received 510(k) clearance from the United States (“U.S.”) Food and Drug Administration (“FDA”) for four of itsdevices: (i) its Evo cortical electrode technology for recording, monitoring, and stimulating brain tissue for up to 30 days (“EvoCortical”), (ii) its Evo® sEEG electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulationequipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain (“Evo sEEG”); (iii) itsOneRF ablation system for creation of radiofrequency lesions in nervous tissue for functional neurosurgical procedures (the “OneRFAblation System”) and (iv) our OneRF TN ablation system for use in procedures to create radiofrequency (RF) lesions for thetreatment of pain, or for lesioning nerve tissue for functional neurosurgical procedures (“OneRF TN Ablation System”, together with The Company is based in Eden Prairie, Minnesota. Global Economic Conditions Generally, worldwide economic conditions remain uncertain, particularly due to the conflicts between Russia and Ukraine and in theMiddle East, disruptions in the banking system and financial markets, and increased inflation. The general economic and capitalmarket conditions both in the U.S. and worldwide, have been volatile in the past and at times have adversely affected the Company’saccess to capital and increased the cost of capital. The capital and credit markets may not be available to support future capital raising The Company’s operating results could be materially impacted by changes in the overall macroeconomic environment and othereconomic factors. Changes in economic conditions, supply chain constraints, logistics challenges, labor shortages, the conflicts inUkraine and the Middle East, disruptions in the banking system and financial markets, and steps taken by governments and central Basis of presentation The accompanying unaudited condensed financial statements have been prepared by the Company, pursuant to the rules andregulations of the U.S. Securities and Exchange Commission (the “SEC”). Certain information and footnote disclosures normallyincluded in financial statements prepared in accordance with U.S. generally accepted accounting principles (U.S. GAAP) have beencondensed or omitted pursuant to such rules and regulations. The condensed financial statements may not include all disclosuresrequired by U.S. GAAP; however, the Company believes that the disclosures are adequate to make the information presented not NeuroOne Medical Technologies CorporationNotes to Condensed Financial Statements In the opinion of management, all adjustments, consisting of only normal recurring adjustments that are necessary to present fairly thefinancial position, results of operations, and cash flows for the interim periods, have been made. The results of operations for the NOTE 2 - Going Concern The accompanying condensed financial statements have been prepared on the basis that the Company will continue as a goingconcern. The Company has incurred losses since inception, negative cash flows from operations, and an accumulated deficit of $80.0million as of December 31, 2025. To date, the Company’s revenues have not been sufficient to cover its full operating costs, and assuch, it has been dependent on funding operations through the issuance of debt and sale of equity securities which previously resultedin substantial doubt regarding the Company’s ability to continue as a going concern. As of December 31, 2025, the Company had$3.6million in cash and cash equivalents. The Company believes its current available cash and cash equivalents coupled with theanticipated increase in product revenues from minimum purchases and improved gross margins under the distribution agreement withZimmer (See “Note 7– Zimmer Distribution Agreement and Other Product Revenue”) and forecasted operating expense reductions, The Company intends to fund ongoing activities by utili